Safe therapy of osteoarthritis: place of topical nonsteroidal anti-inflammatory drugs

The article discusses the social significance of osteoarthritis as a widespread disease that develops mainly in older people, which makes it difficult to carry out anti-inflammatory and analgesic therapy due to the frequent combination of osteoarthritis with other diseases at this age, the need to treat comorbid conditions, which is often poorly combined with systemic therapy with non-steroidal anti-inflammatory drugs. It is noted that osteoarthritis not only worsens the quality of life of patients, but also leads to a decrease in the length of their life, which emphasizes the medical and social importance of conducting the safest possible therapy for this disease. Data on the negative impact of the presence of chronic pain on the progression of osteoarthritis are presented. The negative aspects of the use of oral forms of non-steroidal anti-inflammatory drugs are discussed: the development of adverse events primarily from the gastrointestinal tract and cardiovascular system, the negative effect on the synthesis of glycoaminoglycans («chondronegative effect»). Discusses the place of topical forms of NSAIDs in the treatment of patients with osteoarthritis in accordance with the recommendations of the International society for the use of topical forms of NSAIDs in the management of patients with osteoarthritis of large and small joints. Data on transdermal transport of the topical form of diclofenac, a small molecule with lipophilic properties, are presented. Data on the effectiveness of topical forms of diclofenac in comparison with oral forms are presented according to numerous randomized controlled trials, and the comparable effectiveness of both forms of diclofenac is demonstrated, with maximum safety of the topical form. A special structure of Voltaren® Emulgel (Voltaren® Emulgel), combining the properties of a gel and cream, which provides rapid transdermal penetration and longer retention of the active substance in the area of inflammation, is described, as well as a special prolonged form of Voltaren® Emulgel), which creates additional convenience for use.

1. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A. et. al. Estimates of the prevalence of arthritis and other rheumatic conditions in thr Unated States. Rart II. Arthritis Rheum. 2008;58(1):26–35. doi: 10.1002/art.23176.

2. Haugen I.K., Englund M., Aliabadi P., Niu J., Clancy M., Kvien T.K., Felson D.T. Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingeham Osteoarthritis Study. Ann Rheum Dis. 2011;70(9):1581–1586. doi: 10.1136/ard.2011.150078.

3. Felson D.T., Naimark A., Anderson J., Kazis L., Castelli W., Meenan R.F. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1987;30(8):914–918. doi: 10.102/art.1789300811.

4. Jordan J.M., Helmick C.G., Renner J.B., Luta G., Dragomir A.D., Woodard J. et al. Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians. The Johnston Country Osteoarthritis Project. J Rheumatol. 2007;34(1):172–180. Available at: https://pubmed.ncbi.nlm.nih.gov/17216685.

5. Jordan J.M., Helmick C.G., Renner J.B., Luta G., Dragomir A.D., Woodard J. et al. Prevalence of hip symptoms and radiographic and symptomatic hip osteoarthritis in African Americans and Caucasians. The Johnston Country Osteoarthritis Project. J Rheumatol. 2009;36(4):809–815. doi: 10.3899/jrheum.080677.

6. Hannan M.T., Felson D.T., Pincus T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol. 2000;27(6):1513–1517. Available at: https://pubmed.ncbi.nlm.nih.gov/10852280.

7. Zhang Y., Niu J., Kelly-Hayes M., Chaisson C.E., Aliabadi P., Felson D.T. Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: The Framingham Study. Am J Epidemiol. 2002;156(11):1021–1027. doi: 10.1093/aje/kwf141.

8. Galushko E.A., Bolshakova T.Y., Vinogradova I.B., Ivanova O.N., Lesnyak O.M., Menshikova L.V. et al. Structure of rheumatic diseases among adult population of Russia according to data of an epidemiological study (preliminary results). Nauchno-prakticheskaya Rheumatologia = Rheumatology Science and Practice. 2009;47(1):11–17. (In Russ.) doi: 10.14412/1995-4484-2009-136.

9. Vina E.R., Kwoh C.K. Epidemiology of osteoarthritis: literature update. Curr Opin Rheumatol. 2018;30(2):160–167. doi: 10.1097/BOR.0000000000000479.

10. Hall A.J., Stubbs B., Mamas M.A., Myint P.K., Smith T.O. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):938–946. doi: 10.1177/2047487315610663.

11. Hawker G.A., Croxford R., Bierman A.S., Harvey P.J., Ravi B., Stanaitis I., Lipscombe L.L. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PLoS One. 2014;9(3):e91286. doi: 10.1371/journal.pone.0091286.

12. Majeed M.H., Ali A.A., Khalil H.A., Bacon D., Imran H.M. A Review of the Pharmacological Management of Chronic Pain in Patients with Heart Failure. Innov Clin Neurosci. 2019;16(11–12):25–27. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006868.

13. Haugen I.K., Ramachandran V.S., Misra D., Neogi T., Niu J., Yang T. et al. Hand osteoarthritis in relation on mortality and incidence of cardiovascular disease: data from Framingham Heart Study. Ann Rheum Dis. 2015;74(1):74–81. doi: 10.1136/annrheumdis-2013-203789.

14. Nüesch E., Dieppe P., Reichenbach S., Williams S., Iff S., Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011;342:d1165. doi: 10.1136/bmj.d1165.

15. Kluzek S., Sanchez-Santos M.T., Leyland K.M., Judge A., Spector T.D., Hart D. et al. Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle- aged women. Ann Rheum Dis. 2016;75(10):1749–1756. doi: 10.1136/annrheumdis-2015-208056.

16. White D.K., Niu J., Zhang Y. Is symptomatic knee osteoarthritis a risk factor for a trajectory of fast decline in gait speed? Results from longitudinal cohort study. Arthr Care Res. 2013;65(2):187–194. doi: 10.1002/acr.21816.

17. Bastick A.N., Belo J.N., Runhaar J., Bierma-Zeinstra S.M. What are the prognostic factors for radiographic progression of knee osteoarthritis? A metaanalysis. Clin Orthop Relat Res. 2015;473(9):2969–2989. doi: 10.1007/s11999-015-4349-z.

18. McAlindon T.E., Bannuru R.R., Sullivan M.C., Arden N.K., Berenbaum F., Bierma-Zeinstra S.M. et al. OARSI Guidelines for the non-surgical management of knee osteoarthritis. Ostearthr Cartilage. 2014;22(3):363–388. doi: 10.106/j.joca.2014.01.003.

19. Hararfoosh S., Asghar W., Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–847. doi: 10.18433/j3vw2f.

20. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human articular cartilage. Br J Pharmacol.2000;131(7):1413–1421. doi: 10.1038/sj.bjp.0703710.

21. Chichasova N.V. Treatment of osteoarthritis: the effect of various antiinflammatory drugs on the cartilage tissue. RMZH = RMJ. 2005;13(8):539–542. (In Russ.) Available at: https://www.rmj.ru/articles/obshchie-stati/Lechenie_osteoartroza_vliyanie_na_hryaschevuyu_tkany_razlichnyh_protivovospalitelynyh_preparatov/.

22. Robert E., Nune V.D., Buckner S., Latchem S. Paracetamol: not safe as we thought? A systematic review of observational studies. Ann Rheum Dis. 2016,75:552–559. doi: 10.1136/annrheumdis-2014-206914.

23. Bruyère O., Honvo G., Veronese N., Arden N.K., Branco J., Curtis E.M. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism. 2019;49(3):337–350. doi: 10.1016/j.semarthrit.2019.04.008.

24. Bannuru R.R., Osani M.C., Vaysbrot E.E., Arden N.K., Bennell K., Bierma- Zeinstra S.M.A. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartilage. 2019;27(11):1578–1589. doi: 10.1016/j.joca.2019.06.011.

25. Kolasinski S.L., Neogi T., Hochberg M.C., Oatis C., Guyatt G., Block J. et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand? Hip and knee. Arthr Rheumatol. 2020;72(2):220–233. doi: 10.1002/art.41142.

26. Altman R., Brandt K., Hochberg M., Moskowitz R., Bellamy N., Bloch D.A. et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of Osteoarthritis Research Society. Results from a workshop. Ostearthr Cartilage. 1996;4(4):217–243. doi: 10.1016/s1063-4584(5)80101-3.

27. Cordero J.A., Alacron L., Escribano E. A comparative study of the transdermal penetration of a series of nonsteroidal anti-inflammatory drugs. Pharm Sci. 1997;86:503–508. doi: 10.1021/js960346.

28. Altman R., Bosch B., Brune K., Patrignani P., Young C. Advances in NSAID development evolution of diclofenac products using pharmaceutical technology. Drugs. 2015;75(8):859–877. doi: 10.1007/s40265-015-0392-z.

29. Rainsford K., Kean W., Ehrlich G. Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin. 2008;24(10):2967–2992. doi: 10.1185/03007990802381364.

30. Brune K. Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Curr Med Res Opin. 2007;23(12):2985–2995. doi: 10.1185/030079907X242584.

31. Blot L., Marcelis A., Devogelaer J., Manicourt D.-H. Effects of diclophenac, acetophenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000;13(7):1413–1421. doi: 10.1038/sj.bjp.0703710.

32. El Hajjaji H., Marcelis A., Devogelaer J.P., Manicourt D.H. Celexoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol. 2003;30(11):2444–2451. Available at: https://pubmed.ncbi.nlm.nih.gov/14677191/.

33. Badokin V.V. The effect of non-steroidal anti-inflammatory drugs on the metabolism of articular cartilage. RMZH = RMJ. 2013;(32):1657–1661. (In Russ.) Available at: https://www.rmj.ru/articles/revmatologiya/Vliyanie_nesteroidnyh_protivovospalitelynyh_preparatov_na_metabolizm_sustavnogo_hryascha.

34. Ajazuddin, Alexander A., Khichariya A., Gupta S., Patel R.J., Giri T.K., Tripathi D.K. Recent expansions in an emergent novel drug delivery technology: Emulgel. J Control Release. 2013;171(2):122–132. doi: 10.1016/j.jconrl.2013.06.30.

35. Niethard F.U., Gold M.S., Solomon G.S., Liu J.M., Unkauf M., Albrecht H.H., Elkik F. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol. 2005;32(12):2384–2392. Available at: https://www.gskhealthpartner.com/content/dam/cf-consumer-healthcare/health-professionals/en_IN/pdf/NIETHARD_2005%20OA_KNEE.pdf.

36. Zacher J., Burger K.J., Farber L., Grave M., Abberger H., Bertsch K. Topisches Diclofenac Emulgel versus orales Ibuprofen in der Therapie der aktivierten Arthrose der Fingergelenke (Heberden- und/oder Bouchard-Arthrose). Akt Rheumatol. 2001;26(1):7–14. doi: 10.1055/s-2001-11369.

37. Derry S., Moore R.A., Gaskell H., McIntyre M., Wiffen P.J. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database of Syst Rev. 2015;(6):CD007402. doi: 10.1002/14651858.CD007402.pub3.

38. Predel H.G., Hamelsky S., Gold M., Giannetti B. Efficacy and safety of diclofenac diethylamine 2.32% gel in acute ankle sprain. Med Sci Sports Exerc. 2012;44(9):1629–1636. doi: 10.1249/MSS.0b013e318257ed41.

39. Predel H.G., Giannetti B., Pabst H., Schaefer A., Hug A.M., Burnett I. Efficacy and safety of diclofenac diethylamine 1.16% gel in acute neck pain: a randomized, doubleblind, placebocontrolled study. BMC Musculoskelet Disord. 2013;14(1):250. doi: 10.1186/14712474-14-250.

40. González de Vega C., Speed C., Wolfarth B., González J. Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: A multicentre, randomised, blinded, controlled and non-inferiority trial. Int J Clin Pract. 2013;67(10):979–989. doi: 10.1111/ijcp.12219.

41. Diaz R.L., Gardeazabal J., Manrique P., Ratón J.A., Urrutia I., Rodríguez- Sasiain J.M., Aguirre C. Greater allergenicity of topical ketoprofen in contact dermatitis confirmed by use. Contact Dermatitis. 2006;54(5):239–243. doi: 10.1111/j.0105-1873.2006.00797.x.

42. Hagen M., Baker M. Skin penetration and tissue permeation after topical administration of diclofenac. Curr Med Res Opin. 2017;33(9):1623–1634. doi: 10.1080/03007995.2017.1352497